Huntington's disease: which drugs might help patients?

No abstract is available for this paper.

• Publication year

  2004

• Venue

  IDrugs : the investigational drugs journal

• Publication date

  2004-04-01

• Fields of study

  Medicine

• Identifiers
  PMID 15057641
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Different phenotypic expression in monozygotic twins with Huntington disease

  2004cited by this paper
• Genetic and environmental factors in the pathogenesis of Huntington’s disease

  2004cited by this paper
• Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease

  2004cited by this paper
• Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset.

  2004cited by this paper
• Minocycline and doxycycline are not beneficial in a model of Huntington's disease

  2003cited by this paper
• Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice

  2003cited by this paper
• Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease.

  2003cited by this paper
• Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation.

  2003cited by this paper
• Huntington's disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation

  2003cited by this paper
• Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1.

  2003cited by this paper
• Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes

  2003cited by this paper
• Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?

  2003cited by this paper
• Huntingtin aggregation and toxicity in Huntington's disease.

  2003cited by this paper
• Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease

  2003cited by this paper
• Cystamine Inhibits Caspase Activity

  2003cited by this paper
• Role of proteolysis in polyglutamine disorders

  2003cited by this paper
• Dosage effects of riluzole in Huntington’s disease

  2003cited by this paper
• A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study.

  2003cited by this paper
• Ascorbate treatment attenuates the Huntington behavioral phenotype in mice

  2003cited by this paper
• Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

  2003cited by this paper
• Transcriptional abnormalities in Huntington disease.

  2003cited by this paper
• Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice

  2003cited by this paper
• Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine

  2002cited by this paper
• Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain.

  2002cited by this paper
• Therapeutic Effects of Cystamine in a Murine Model of Huntington's Disease

  2002cited by this paper
• Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.

  2002cited by this paper
• Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells.

  2002cited by this paper
• Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines

  2002cited by this paper
• MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment

  2002cited by this paper
• Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects.

  2002cited by this paper
• A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids

  2002cited by this paper
• Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease

  2002cited by this paper
• Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease.

  2002cited by this paper
• A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila

  2002cited by this paper
• Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation

  2002cited by this paper
• Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease.

  2002cited by this paper
• Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay

  2002cited by this paper
• Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease

  2002cited by this paper
• Huntington’s disease: A randomized, controlled trial using the NMDA-antagonist amantadine

  2002cited by this paper
• Environmental enrichment slows disease progression in R6/2 Huntington's disease mice

  2002cited by this paper
• Amantadine in Huntington's disease: open-label video-blinded study

  2002cited by this paper
• Olanzapine for Huntington's Disease: An Open Label Study

  2002cited by this paper
• Olanzapine in Huntington's disease

  2002cited by this paper
• Lipoic acid improves survival in transgenic mouse models of Huntington's disease

  2001cited by this paper
• Histone deacetylase inhibitors reduce polyglutamine toxicity

  2001cited by this paper
• Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease.

  2001cited by this paper
• Riluzole in Huntington's disease (HD): an open label study with one year follow up

  2001cited by this paper
• Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila

  2001cited by this paper
• Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease

  2001cited by this paper
• A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease

  2001cited by this paper
• Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease.

  2001cited by this paper
• Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model.

  2001cited by this paper
• Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease

  2001cited by this paper
• N‐Acetylaspartate and DARPP‐32 levels decrease in the corpus striatum of Huntington's disease mice

  2000cited by this paper
• Decreased expression of striatal signaling genes in a mouse model of Huntington's disease.

  2000cited by this paper
• Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice.

  2000cited by this paper
• Delaying the onset of Huntington's in mice

  2000cited by this paper
• The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.

  2000cited by this paper
• Abnormal Synaptic Plasticity and Impaired Spatial Cognition in Mice Transgenic for Exon 1 of the Human Huntington's Disease Mutation

  2000cited by this paper
• Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy.

  2000cited by this paper
• Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice.

  2000cited by this paper
• Brain-derived neurotrophic factor in Huntington disease.

  2000cited by this paper
• Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease

  2000cited by this paper
• Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease.

  2000cited by this paper
• Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

  2000cited by this paper
• Transcriptional dysregulation in Huntington's disease.

  2000cited by this paper
• Mutant Huntingtin Expression in Clonal Striatal Cells: Dissociation of Inclusion Formation and Neuronal Survival by Caspase Inhibition

  1999cited by this paper
• Influence of lamotrigine on progression of early Huntington disease

  1999cited by this paper
• Impaired synaptic plasticity in mice carrying the Huntington's disease mutation.

  1999cited by this paper
• Enhanced sensitivity to N‐methyl‐D‐aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease

  1999cited by this paper
• A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.

  1999cited by this paper
• Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

  1999cited by this paper
• Evidence for the GluR6 gene associated with younger onset age of Huntington’s disease

  1999cited by this paper
• Differential clinical and motor control function in a pair of monozygotic twins with Huntington's disease

  1999cited by this paper
• Riluzole therapy in Huntington's disease (HD)

  1999cited by this paper
• Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene.

  1998cited by this paper
• Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates

  1998cited by this paper
• Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

  1997cited by this paper
• Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.

  1997cited by this paper
• Energy metabolism defects in Huntington's disease and effects of coenzyme Q10

  1997cited by this paper
• Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease.

  1997cited by this paper
• Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.

  1996cited by this paper
• Loss of cannabinoid receptors in the substantia nigra in Huntington's disease.

  1993cited by this paper

• A Review on Huntington ’ s Disease

  2018cites this paper
• Neuroprotective strategies of solanesol in mitochondrial impairment in experimentally induced Huntington disease

  2018cites this paper
• Translatable Models of Brain and Cognitive Reserve

  2017cites this paper
• Environmental factors as modulators of neurodegeneration: insights from gene-environment interactions in Huntington's disease.

  2015cites this paper
• Review: Environmental enrichment and brain repair: harnessing the therapeutic effects of cognitive stimulation and physical activity to enhance experience‐dependent plasticity

  2014cites this paper
• Translating preclinical environmental enrichment studies for the treatment of autism and other brain disorders: comment on Woo and Leon (2013).

  2013cites this paper
• Enhancement of cognitive function in models of brain disease through environmental enrichment and physical activity.

  2013cites this paper
• Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.

  2013cites this paper
• Environmental Enrichment and Gene–Environment Interactions in Mouse Models of Brain Disorders

  2010cites this paper
• The anxiolytic effect of environmental enrichment is mediated via amygdalar CRF receptor type 1

  2010cites this paper
• Gene-environment interplay in neurogenesis and neurodegeneration

  2009cites this paper
• The neurobiology of brain and cognitive reserve: mental and physical activity as modulators of brain disorders.

  2009cites this paper
• Modeling brain reserve: experience-dependent neuronal plasticity in healthy and Huntington's disease transgenic mice.

  2009cites this paper
• Effects of enriched environment on animal models of neurodegenerative diseases and psychiatric disorders.

  2008cites this paper
• Molecular mechanisms mediating pathological plasticity in Huntington's disease and Alzheimer's disease

  2007cites this paper
• Enviromimetics: exploring gene environment interactions to identify therapeutic targets for brain disorders

  2007cites this paper
• Dissecting cause and effect in the pathogenesis of psychiatric disorders: genes, environment and behaviour.

  2007cites this paper
• Enriched environments, experience-dependent plasticity and disorders of the nervous system

  2006cites this paper
• Huntington disease: a nursing perspective.

  2005cites this paper
• BRIEF REVIEW GENE-ENVIRONMENT INTERACTIONS, NEURONAL DYSFUNCTION AND PATHOLOGICAL PLASTICITY IN HUNTINGTON'S DISEASE

  2005cites this paper
• Nature, nurture and neurology: gene–environment interactions in neurodegenerative disease

  2005influential citation
• Novel therapeutic targets for Huntington’s disease

  2005cites this paper
• Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine

  2005cites this paper
• GENE–ENVIRONMENT INTERACTIONS, NEURONAL DYSFUNCTION AND PATHOLOGICAL PLASTICITY IN HUNTINGTON'S DISEASE

  2005cites this paper
• Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease.

  2004influential citation